Intensified intravitreal bevacizumab treatment regime for type 1 and 2 idiopathic macular telangiectasia  

作　　者：Christos Chryssafis Aljoscha Steffen Neubauer Efstathios Papadopoulos Kai Januschowski Karl Thomas Boden Peter Szurman 

机构地区：[1]Knappschafts Eye Clinic, Sulzbach 66280, Saar, Germany [2]Eye Clinic Ludwig Maximilians University, Munich 80336,Germany [3]Department of Experimental Ophthalmosurgery, Eye Clinic Eberhard-Karls University, Ttibingen 72074, Germany

出　　处：《International Journal of Ophthalmology(English edition)》2016年第7期1076-1078,共3页国际眼科杂志（英文版）

摘　　要：Dear Sir,I am Dr.Christos Chryssafis,from the Knappschafts Eye Clinic,Sulzbach,Saar,Germany.I write to present the results of our study about an intensified intravitreal bevacizumab（IVB）injections regime for type 1 and 2idiopathic macular telangiectasia（IMT）.Treatment by thermal laser photocoagulation,photodynamic therapy,Dear Sir,I am Dr.Christos Chryssafis,from the Knappschafts Eye Clinic,Sulzbach,Saar,Germany.I write to present the results of our study about an intensified intravitreal bevacizumab（IVB）injections regime for type 1 and 2idiopathic macular telangiectasia（IMT）.Treatment by thermal laser photocoagulation,photodynamic therapy,

关 键 词：IMT TYPE 

分 类 号：R774.5[医药卫生—眼科]